I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Jill Leversage Biography and Net Worth

Director of Aurinia Pharmaceuticals

Jill Leversage was appointed as an Independent Director of Aurinia in November 2019. Jill began her finance career at Burns Fry Ltd. and has held senior level positions at BMO Financial Group, RBC Capital Markets, and TD Securities. Jill has served on a number of public and not-for-profit corporate boards including MAG Silver Corp, RE Royalty Ltd., Insurance Corporate of BC, CMAIO, and the Vancouver Airport Authority. Jill is a Fellow of the Institute of Chartered Professional Accountants of British Columbia and also a Chartered Business Valuator (ret.) of the Canadian Institute of Chartered Business Valuators.

What is Jill Leversage's net worth?: The estimated net worth of Jill Leversage is at least $26,677.00 as of May 11th, 2021. Ms. Leversage owns 3,700 shares of Aurinia Pharmaceuticals stock worth more than $26,677 as of November 4th. This net worth approximation does not reflect any other assets that Ms. Leversage may own. Learn More about Jill Leversage's net worth.
How do I contact Jill Leversage?: The corporate mailing address for Ms. Leversage and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]. Learn More on Jill Leversage's contact information.
Has Jill Leversage been buying or selling shares of Aurinia Pharmaceuticals?: Jill Leversage has not been actively trading shares of Aurinia Pharmaceuticals over the course of the past ninety days. Most recently, on Monday, December 13th, Jill Leversage bought 1,600 shares of Aurinia Pharmaceuticals stock. The stock was acquired at an average cost of $20.04 per share, with a total value of $32,064.00. Learn More on Jill Leversage's trading history.
Who are Aurinia Pharmaceuticals' active insiders?: Aurinia Pharmaceuticals' insider roster includes Matthew Donley (VP), Peter Greenleaf (CEO), Robert Huizinga (EVP), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Aurinia Pharmaceuticals?: In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 18,249 shares worth more than $96,902.19. The most recent insider tranaction occured on August, 6th when insider Scott Michael Habig sold 18,249 shares worth more than $96,902.19. Insiders at Aurinia Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.
Information on this page was last updated on 8/6/2024.

Jill Leversage Insider Trading History at Aurinia Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2021	Buy	1,600	$20.04	$32,064.00
5/11/2021	Buy	2,500	$10.96	$27,400.00	3,700
1/29/2021	Buy	1,200	$16.03	$19,236.00	1,200

Jill Leversage Buying and Selling Activity at Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Today's Range

Now: $7.21

$7.03

$7.28

50 Day Range

MA: $7.04

$6.53

$7.49

2 Week Range

Now: $7.21

$4.71

$10.05

Volume

1,196,678 shs

Average Volume

1,596,917 shs

Market Capitalization

$1.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

I was wrong. Dead wrong.

From Porter & Company | Ad